Data from more than 20 programs, including new research from cell therapy and targeted protein degradation platforms, showcase the depth and breadth of BMS' diverse portfolio and ongoing leadership in blood diseases and beyond
PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASH--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 90 data disclosures, including 18 oral presentations, across company-sponsored studies, investigator-sponsored studies and collaborations from its hematology and cell therapy research programs at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 7 to 10 in San Diego, California. These data underscore the depth and diversity of the company's approved products and investigational pipeline and spotlight the next wave of innovative treatment approaches with the potential to transform patient outcomes across hematology and other areas of disease.
"Our data at ASH reflect our unique ability to address unmet patient needs with our industry-leading cell therapy portfolio and the continued expansion of our work in targeted protein degradation. These advances have been built on decades of specialized research and experience across clinical development and dedication to patient-centric treatment approaches," said Anne Kerber, senior vice president, head of late clinical development, Hematology, Oncology, and Cell Therapy (HOCT), Bristol Myers Squibb. "This meeting provides us with an opportunity to reinforce our commitment to this critical area of research and highlight our current efforts to transform how hematologic diseases are treated."
Key data being presented by Bristol Myers Squibb and its partners at the 2024 ASH Annual Meeting and Exposition include:
Cell Therapy
- Multiple analyses underscoring durable efficacy and well-established safety of the best-in-class profile of Breyanzi (lisocabtagene maraleucel; liso-cel) in large B-cell lymphoma (LBCL), including five-year follow-up overall survival (OS) data from the TRANSCEND NHL-001 trial, new data from the Phase 3 TRANSFORM 2L LBCL study showing deeper and more durable responses with Breyanzi over former standard of care using circulating tumor DNA (ctDNA) as an earlier surrogate of clinical outcome, and compelling real-world data from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
- Longer-term results from TRANSCEND FL and TRANSCEND CLL 004 reinforcing Breyanzi's best-in-class and best-in-disease profile in relapsed or refractory (R/R) follicular lymphoma (FL), and its durable responses, sustained complete remissions and updated safety profile in patients with R/R chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
- Additional evaluations highlighting efficacy and safety from the Phase 1/2 TRANSCEND CLL 004 trial analyzing Breyanzi in combination with ibrutinib in patients with R/R CLL and SLL
- New analysis highlighting global manufacturing capability, reliability and timely delivery for Abecma (idecabtagene vicleucel; ide-cel) in relapsed or refractory multiple myeloma (RRMM)
- First OS and progression-free survival results from a Phase 1 study of GPRC5D-directed CAR T cell therapy (BMS-986393/CC-95266) across all dose levels, supporting first-in-class potential in both B-cell maturation antigen (BCMA)-naïve and BCMA-exposed patients with RRMM
- Cell therapy data highlighting its potential beyond blood cancers, with updated Phase 1 data for CD19 NEX-T CAR T in severe, refractory autoimmune diseases, for the first time including patients with multiple sclerosis
Anemia
- New COMMANDS trial analyses and real-world evidence on long-term benefit of Reblozyl (luspatercept-aamt) for patients with lower-risk myelodysplastic syndromes (MDS) across subgroups, including patients with ring sideroblasts (RS) and low baseline serum erythropoietin (sEPO)
Targeted Protein Degradation
- Updated results from Phase 1/2 CC-220-MM-001 trial supporting clinical and pharmacological activity of iberdomide combined with daratumumab and dexamethasone in transplant-ineligible, newly-diagnosed MM patients, including those with high-risk markers
- Results from Phase 1/2 CA057-003 trial evaluating an all-oral combination of mezigdomide and novel agents (EZH2, BET and MEK inhibitors), showing promising efficacy and no new safety signals in patients with RRMM
- Multiple data sets highlighting the promising clinical profile of golcadomide across LBCL and FL, including new analyses from Phase 1b DLBCL-001 study showing golcadomide plus R-CHOP has high minimal residual disease (MRD) negativity in high-risk 1L LBCL, and longer follow-up from the Phase 1/2 NHL-001 study demonstrating the potential of golcadomide in combination with rituximab for R/R FL and R/R LBCL
- Preclinical analysis evaluating development of fetal hemoglobin (HbF)-activating CELMoD agent BMS-986470 for the treatment of sickle cell disease
- Multiple preclinical analyses evaluating potential first-in-class CELMoD agent BMS-986397 targeting casein kinase 1α (CK1α) in acute myeloid leukemia and high-risk MDS harboring functional TP53
- Preclinical results for potential first-in-class ligand-directed degrader of BCL6 BMS-986458 demonstrating anti-tumor efficacy in B-cell non-Hodgkin lymphoma (NHL)
Additional information about BMS' presence at the meeting can be found on the ASH website.
Selected BMS studies at the 2024 ASH Annual Meeting and Exposition include:
Abstract Title | Author | Presentation Type/# | Session Title | Session Date/Time (PST) |
Autoimmune Disease | ||||
Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies | Fabian Müller | Poster Presentation #2088 | Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Acute Myeloid Leukemia (AML) | ||||
Synergistic Activity of BMS-986397, a First-in-Class α Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML) | Carmen Jimenez | Poster Presentation #1395 | Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Beta Thalassemia | ||||
Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial | John Porter | Poster Presentation #2475 | Session: 112. Thalassemia and Globin Gene Regulation: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia | Khaled Musallam | Poster Presentation #3857 | Session: 112. Thalassemia and Globin Gene Regulation: Poster III | Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Lymphoma | ||||
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized TRANSFORM Study | Ash Alizadeh | Oral Presentation #72 | Session: 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas | Saturday, December 7, 2024: 10:45 AM (1:45 PM ET) |
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry | Maria Silvina Odstrcil Bobillo | Oral Presentation #470 | Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma | Sunday, December 8, 2024: 9:45 AM (12:45 PM ET) |
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry | Sairah Ahmed | Oral Presentation #472 | Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma | Sunday, December 8, 2024: 10:15 AM (1:15 PM ET) |
Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL) | Arnaud Amzallag | Oral Presentation #579 | Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL | Sunday, December 8, 2024: 12:30 PM (3:30 PM ET) |
Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study | Julio C. Chavez | Poster Presentation #3018 | Session: 623. Mantle Cell, Follicular, Waldenströms, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Jeremy Abramson | Poster Presentation #3125 | Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up | Jeremy Abramson | Poster Presentation #3130 | Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Degradation of Ikaros Induces Neutropenia through Altered Transcriptional Programming across Multiple Stages of Neutrophil Development and Maturation | Ajit Dhadve | Poster Presentation #2523 | Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) | Alexander P. Boardman | Poster Presentation #3028 | Session: 623. Mantle Cell, Follicular, Waldenström, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Jean-Marie Michot | Oral Presentation #869 | Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications | Monday, December 9, 2024: 3:45 PM (6:45 PM ET) |
Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study | William Wierda | Oral Presentation #887 | Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life | Monday, December 9, 2024: 3:45 PM (6:45 PM ET) |
Deciphering the Mechanism of Action of the Novel CELMoD, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma | Caroline Huber | Oral Presentation #955 | Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma | Monday, December 9, 2024: 4:30 PM (7:30 PM ET) |
BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma | Lynda Groocock | Oral Presentation #957 | Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma | Monday, December 9, 2024: 5:00 PM (8:00 PM ET) |
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004 | Tanya Siddiqi | Poster Presentation #4633 | Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III | Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up | Loretta J. Nastoupil | Poster Presentation #4387 | Session: 623. Mantle Cell, Follicular, Waldenström, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III | Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Multiple Myeloma | ||||
Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial | Michael Amatangelo | Poster Presentation #1973 | Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results | Susan Bal | Poster Presentation #2069 | Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial | Luciano Costa | Oral Presentation #677 | Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond | Sunday, December 8, 2024: 5:30 PM (8:30 PM ET) |
Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide | Tracy Chow | Poster Presentation #3261 | Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up | Barry Paul | Poster Presentation #3388 | Session: 655. Multiple Myeloma: Cellular Therapies: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma | Surbhi Sidana | Poster Presentation #3476 | Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
| Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis | Maria Chaudhry | Poster | Session: 655. Multiple Myeloma: Cellular Therapies: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (R/R) Multiple Myeloma | Susan Bal | Oral Presentation #922 | Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies | Monday, December 9, 2024: 3:30 PM (6:30 PM ET) |
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial | Irwindeep Sandhu | Oral Presentation #1025 | Session: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma | Monday, December 9, 2024: 5:30 PM (8:30 PM ET) |
Myelodysplastic Syndromes | ||||
The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe | Maria Diez-Campelo | Oral Presentation #118 | Session: 908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care | Saturday, December 7, 2024: 10:15 AM (1:15 PM ET) |
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial | Guillermo Garcia-Manero | Oral Presentation #350 | Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS | Saturday, December 7, 2024: 4:15 PM (7:15 PM ET) |
Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial | Valeria Santini | Poster Presentation #1818 | Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial | Guillermo Garcia-Manero | Poster Presentation #1832 | Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia | Pramila Krishnamurthy | Poster Presentation #2425 | Session: 908. Outcomes Research: Myeloid Malignancies: Poster I | Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET) |
Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study | Esther N. Oliva | Poster Presentation #3216 | Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain | Maria Diez-Campelo | Poster Presentation #5055 | Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III | Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53 | Carmen Jiminez | Poster Presentation #4142 | Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III | Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Myelofibrosis | ||||
Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial | Haifa Kathrin Al-Ali | Oral Presentation #482 | Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents | Sunday, December 8, 2024: 9:45 AM (12:45 PM ET) |
Burden and Clinical Outcomes in Patients (pts) with Myelofibrosis (MF) and Anemia Treated with Ruxolitinib (RUX): Data from the Veterans Affairs Corporate Data Warehouse (VACDW) | John O. Mascarenhas | Poster Presentation #3807 | Session: 908. Outcomes Research: Myeloid Malignancies: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
Sickle Cell Disease | ||||
Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD for the Treatment of Sickle Cell Disease | Emily Rychak | Oral Presentation #169 | Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease | Saturday, December 7, 2024: 2:00 PM (5:00 PM ET) |
Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease | Thiago T. Maciel | Oral Presentation #621 | Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications: Lessons from Pre-clinical Models | Sunday, December 8, 2024: 5:00 PM (8:00 PM ET) |
Thrombosis and Anticoagulation | ||||
Reversal of The Anticoagulant Effect of Milvexian by 4-Factor PCC and rFVIIa in Healthy Participants* | Victor Dishy | Poster Presentation #2628 | Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II | Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET) |
*Sponsored by the Bristol Myers Squibb-Johnson & Johnson Collaboration
Reblozyl is being developed and commercialized through a global collaboration with Merck following Merck's acquisition of Acceleron Pharma, Inc. in November 2021.
Abecma is being jointly developed and commercialized in the U.S. as part of a Co-Development, Co-Promotion, and Profit Share Agreement between Bristol Myers Squibb and 2seventy bio.
About Milvexian*
Milvexian is an investigational oral, highly selective Factor XIa (FXIa) inhibitor, part of a new class of anticoagulants in development aimed at preventing harmful clotting that restricts blood flow (thrombosis) while preserving the normal clotting process (hemostasis). As a result, milvexian could potentially reduce major cardiovascular events due to harmful clotting without significantly increasing the risk of bleeding.
Contacts
Bristol Myers Squibb
Media Inquiries:
media@bms.com
Investors:
investor.relations@bms.com
Read full story here
